Nautilus Biotechnology Inc (NAUT)
$2.92
Performance
- $2.77$2.94$2.92
5.14%
Downside
Day's Volatility :5.78%
Upside
0.68%
- $1.50$4.65$2.92
48.63%
Downside
52 Weeks Volatility :67.74%
Upside
37.2%
Returns
| Period | Nautilus Biotechnology Inc | |
|---|---|---|
3 Months | -7.3% | |
6 Months | -2.01% | |
1 Year | 70.76% | |
3 Years | -71.09% |
Highlights
Market Capitalization | 366.2M |
Book Value | $2.22 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.47 |
Wall Street Target Price | 5.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -13.37% |
Return On Equity TTM | -19.93% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -70.8M |
Diluted Eps TTM | -0.47 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.56 |
EPS Estimate Next Year | -0.73 |
EPS Estimate Current Quarter | -0.17 |
EPS Estimate Next Quarter | -0.19 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 71.23%
Technicals Summary
Sell
Neutral
Buy
Nautilus Biotechnology Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Nautilus Biotechnology Inc | 19.18% | -2.01% | 70.76% | -71.09% | -71.09% |
 Moderna, Inc. | 8.62% | -38.31% | -54.89% | -50.93% | 320.86% |
 Regeneron Pharmaceuticals, Inc. | -1.38% | 9.73% | 9.82% | 65.7% | 115.07% |
 Novo Nordisk A/s | -1.43% | 23.95% | 58.41% | 192.13% | 336.59% |
 Seagen, Inc. | 0.74% | 10.42% | 83.05% | 20.41% | 247.89% |
 Vertex Pharmaceuticals Incorporated | -8.19% | 7.19% | 13.58% | 55.97% | 97.18% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Nautilus Biotechnology Inc | NA | NA | NA | -0.56 | -0.2 | -0.13 | 0.0 | 2.22 |
Moderna, Inc. | 24.73 | NA | 0.0 | -12.72 | -0.22 | -0.07 | 0.0 | 35.32 |
Regeneron Pharmaceuticals, Inc. | 23.18 | 23.18 | 1.75 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
Novo Nordisk A/s | 41.18 | 41.18 | 4.02 | 2.67 | 0.89 | 0.22 | 0.01 | 20.77 |
Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
Vertex Pharmaceuticals Incorporated | 26.38 | 26.38 | 0.5 | 15.04 | 0.23 | 0.14 | 0.0 | 64.05 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Nautilus Biotechnology Inc | Buy | $366.2M | -71.09% | NA | 0.0% |
Moderna, Inc. | Buy | $30.4B | 320.86% | 24.73 | -38.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $88.5B | 115.07% | 23.18 | 30.47% |
Novo Nordisk A/s | Buy | $459.0B | 336.59% | 41.18 | 35.11% |
Seagen, Inc. | Hold | $40.2B | 247.89% | NA | -32.61% |
Vertex Pharmaceuticals Incorporated | Buy | $90.5B | 97.18% | 26.38 | 35.94% |
Institutional Holdings
Perceptive Advisors LLC
7.29%Cercano Management LLC
5.74%Madrona Venture Group, LLC
4.82%BlackRock Inc
2.99%Vanguard Group Inc
2.25%Comprehensive Financial Management LLC
1.77%
Corporate Announcements
Nautilus Biotechnology Inc Earnings
Nautilus Biotechnology Inc’s price-to-earnings ratio stands at None
Read More
Company Information
born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. the extraordinary team at nautilus represents a wide spectrum of disciplines and expertise, including: protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.
Organization | Nautilus Biotechnology Inc |
Employees | 160 |
CEO | Mr. Sujal M. Patel |
Industry | Healthcare |
